Satellite symposia

Satellite symposia are organised by pharmaceutical companies. These symposia are open to all congress participants. Responsibility for the programme content remains by the sponsor.

 ECCO has scheduled parallel satellite symposia on the following days:

  • Thursday, February 15, 2018 at 11:00-12:00 and 18:45-19:45
  • Friday, February 16, 2018 at 07:15-08:15 and  18:35-19:35

Educational lunchtime satellite symposia are scheduled for:

  • Friday, February 16, 2018 at 12:40-13:20

Satellite symposia are held in the Plenary hall (Halle D), Parallel hall (Halle C), Lehar 1-3 (Congress Centre) and Strauss 1-2 (Congress Centre), all on the ground floor.

The programmes of satellite symposia are not affiliated with ECCO.

Satellite symposia

  • Satellite symposium 1a: AbbVie
    Plenary Hall, Hall D, Reed Messe Wien

    AbbVie

    11:00-12:00 Keep CALM and use biomarkers in IBD
    Remo Panaccione, Calgary, Canada
    The story of biomarkers so far
    Jonas Halfvarson, Orebro, Sweden
    Can we trust biomarkers when treating to a target?
    Peter Bossuyt, Bonheiden, Belgium
    Reducing patient burden and societal cost
    Remo Panaccione, Calgary, Canada

    Satellite symposium 1b: Sandoz
    Parallel hall, Hall C, Reed Messe Wien

    sandoz nov div logo pos rgb

    11:00- 12:00 Delivering precision medicine and patient-centred care through a multidisciplinary approach
    Krisztina Gesce, Amsterdam, The Netherlands
    11:00-11:15 Current treatment strategies - optimal care in IBD
    Krisztina Gesce, Amsterdam, The Netherlands
    Antonino Spinelli, Milan, Italy
    11:15-11:30 Managing comorbidities - lessons learned
    Frank Behrens, Frankfurt, Germany
    11:30-11:45 New multidisciplinary approaches: What does the future look like?
    Claudio Fiocchi, Cleveland, United States
    11:45-12:00

    Precision medicine: Current and future considerations - a panel discussion
    Louisa Avedano (EFCCA), Brussels, Belgium
    Frank Behrens, Frankfurt, Germany
    Claudio Fiocchi, Cleveland, United States
    Krisztina Gecse, Amsterdam, The Netherlands
    Antonino Spinelli, Milan, Italy


    N-ECCO Network Meeting: Takeda
    Strauss 1-2, Congress Centre, Reed Messe Wien

    Takeda



    12:45- 13:45 Treating-to-target in IBD - are you ready?
    Catherine Stansfield, Salford, United Kingdom
    12:45-12:55 Why patient empowerment is more important than ever
    Catherine Stansfield, Salford, United Kingdom
    12:55-13:05 Treating-to-target in IBD: Goals, challenges and treatment planning
    Pieter Hindryckx, Ghent, Belgium
    13:05-13:35 Fitting new therapies to patient needs
    Pieter Hindrycks, Ghent, Belgium
    Catherine Stansfield, Salford, Untied Kingdom 
    13:35-13:40 Ask the experts: Treating-to-target in clinical practice
    Chair-moderated Q&A with faculty and Audience
    13:40-13:45 Summary
    Catherine Stansfield, Salford, United Kingdom

    Satellite symposium 2a: Pfizer
    Plenary hall, Hall D, Reed Messe Wien

    Pfizer

    18:45- 19:45 Connecting tomorrow's UC therapies with today's patients
    Matthieu Allez, Paris, France
    18:45-18:50 Welcome & Introduction
    Matthieu Allez, Paris, France
    18:50-19:05 Connecting today's patients with physician realities
    Matthieu Allez, Paris, France
    19:05-19:30 Fitting new therapies to patient needs
    Marc Ferrante, Leuven, Belgium
    19:30-19:40 Q&A
    19:40-19:45 Closing Remarks

    Satellite symposium 2b: Biogen
    Parallel hall, Hall C, Reed Messe Wien

    Biogen Logo Standard cmyk MASTER

    18:45- 19:45 Anti-TNF in IBD - inventory and outlook
    Gert van Assche, Leuven, Belgium
    18:45-18:50 Welcome & Introduction
    Gert van Assche, Leuven, Belgium
    18:50-19:40

    Interactive discussion
    Gert van Assche, Leuven, Belgium

    The Erlangen case
    Raya Atreya, Erlangen, Germany

    The Paris case
    Yoram Bouhnik, Paris, France

    The Southampton case
    Fraser Cummings, Southampton, United Kingdom

    The role of TDM pre- and post-switch
    Geert D'Haens, Amsterdam, The Netherlands

    19:40-19:45 Closing Remarks
    Gert van Assche, Leuven, Belgium

    Satellite symposium 2c: Celltrion
    Lehar 1-3, Congress Centre, Reed Messe Wien

    Celltrionhealthcare TM Updated Symposium 2016



    18:45- 19:45 The value of biosimilar infliximab beyond proven evidence in IBD
    Walter Reinisch, Vienna, Austria
    18:45-19:00 Accumulated experience with biosimilars from the Norwegiean Agency
    Steinar Madsen, Oslo, Norway
    19:00-19:15 Personalised Anti-TNF therapy in Crohn's Disease study: PANTS
    Tariq Ahmad, Exeter, United Kingdom
    19:15-19:30 Early-on optimisation: Therapeutic drug monitoring for personalised treatment
    Walter Reinisch, Vienna, Austria
    19:30-19:45 Panel discussion
    All
  • Satellite Symposium 3a: Takeda
    Plenary hall, Hall D, Reed Messe Wien

    Takeda


    07:15-08:15 Entering a new era of patient-reported outcomes in IBD: Past, present and future
    Peter Higgins, Ann Arbor, United States
    07:15-07:30 Why do patient-reported outcomes matter in Inflammatory Bowel Disease?
    Peter Higgins, Ann Arbor, United States
    07:30-07:50
    Optimising biological therapies with patient-reported outcomes in mind
    Brian Feagan, London, Canada
    07:50-08:05 Continuing development of patient-reported outcomes in Inflammatory Bowel Disease
    Peter Irving, London, United Kingdom
    08:05-08:15 Panel discussion and Q&A
    Peter Higgins, Ann Arbor, United States

    Satellite symposium 3b: Samsung
    Parallel hall, Hall C, Reed Messe Wien

    Samsung Bioepis 2

    07:15-08:15 Biosimilars in IBD: Accompanying along with physicians, nurses and patients
    Alessandro Armuzzi, Rome, Italy
    07:15-07:20 Welcome & Introduction
    Alessandro Armuzzi, Rome, Italy
    07:20-07:25 Biosimilars to physicians: Credible agents
    Alessandro Armuzzi, Rome, Italy
    07:25-07:40 Biosimilars to patients: Is it good for us?
    Louisa Avedano, Brussels, Belgium
    07:40-07:55 Biosimilars to nurses: Implementation and communication with pateints
    Kay Greveson, London, United Kingdom
    07:55-08:05 HCPs' roles for optimised patients' care by biosimilars
    Alessandro Armuzzi, Rome, Italy
    08:05-08:15 Panel discussion and Q&A

    Satellite symposium 3c: Pfizer
    Lehar 1-3, Congress Centre, Reed Messe Wien

    Pfizer


    07:15-08:15 Tackling today's challenges in managing IBD: A practical guide
    Remo Panaccione, Calgary, Canada
    07:15-07:20 Welcome and Introduction
    Remo Panaccione, Calgary, Canada
     07:20-07:35 Addressing comorbid psychosocial risk factors in IBD: Why, what and how?
    Iris Dotan, Tel Aviv, Israel
     07:35-07:50 Rising to the loss of response challenge with anti-TNFs
    Marla Dublinsky, New York, United States
     07:50-08:05 Closing the access gap to biologics: Realising the biosimilar opportunity
    Charlie Lees, Edinburgh, United Kingdom
    08:05-08:15 Q&A/Discussion

    Satellite symposium LS1: AbbVie
    Plenary hall, Hall D, Reed Messe Wien

    AbbVie


    12:40-13:20 Patient First - the reality of extra-intestinal manifestations in IBD - an expert discussion
    Tim Orchard, London, United Kingdom
    Stephan Vavricka, Zurich, Switzerland
     12:40-12:45 In their own words - the patient perspective
     12:45-13:10 EIMs: an expert discussion on the factors that matter
    Tim Orchard, London, United Kingdom
    Stephan Vavricka, Zurich, Switzerland
     13:10-13:20 Key takeaways and Q&A
    Tim Orchard, London, United Kingdom
    Stephan Vavricka, Zurich, Switzerland

    Satellite symposium LS2: Celgene
    Parallel hall, Hall C, Reed Messe Wien      

    Celgene logo

    12:40-13:20 What's your gut feeling about IBD clinical practice today and tomorrow? Interactive case-based discussions
    Jean-Frédéric Colombel, New York, United States
     12:40-12:45 Welcome & Introduction
    Jean-Frédéric Colombel, New York, United States
     12:45-13:00 Case study 1: Current and future approaches to the management of Mild to Moderate Ulcerative Colitis
    Panel discussion with:
    Jean-Frédéric Colombel, New York, United States
    Edouard Louis, Liège, Belgium
    Remo Panaccione, Calgary, Canada
     13:00-13:15 Case study 2: Current and future approaches to the management of Moderate to Severe Crohn's Disease
    Panel discussion with:
    Jean-Frédéric Colombel, New York, United States
    Edouard Louis, Liège, Belgium
    Remo Panaccione, Calgary, Canada
     13:15-13:20 Closing remarks
    Jean-Frédéric Colombel, New York, United States

    Satellite symposium LS3: MSD
    Lehar 1-3, Congress Center, Reed Messe Wien             

    1 2 logo msd
       

    12:40-13:20 PROs, biomarkers and e-Health tools in UC practise
    Glen Doherty, Dublin, Ireland
     12:40-12:50 Welcome and Instruction
    Why do we need to improve our monitoring of UC patients treated with conventional and biological therapies? G
    Glen Doherty, Dublin, Ireland
     12:50-13:20 Interactive discussion:
    Current clinical practise of UC patient monitoring: Goals and pitfalls.
    Future clinical practise of UC patient monitoring: Goals and challenges.
    Glen Doherty, Dublin, Ireland
    Marieke Pierik, Maastricht, The Netherlands

    Satellite symposium LS4: Tillots
    Strauss 1-2, Congress Center, Reed Messe Wien             

    1 2 logo tillotts
       
    12:40-13:20 Physician: Sherlock and Saviour. Quality of life in IBD and insight into microscopic colitis.
    Axel Dignass, Frankfurt, Germany
     12:40-12:45 Welcome and Introduction
    Axel Dignass, Frankfurt, Germany
     12:45-13:00 Microscopic colitis: It is all about quality of life!
    Andreas Münch, Linköping, Sweden
    13:00-13:15 Psychiatric and psychological burden of IBD on quality of life
    Yoram Inspector, London, United Kingdom
    13:15-13:20 Final remarks
    Axel Dignass, Frankfurt, Germany

    Satellite Symposium 4a: Takeda
    Plenary hall, Hall D, Reed Messe Wien

    Takeda


    18:35-19:35 Individualised care for Crohn's Disease: Evolving approaches for a progressive disease
    Jean-Frédéric Colombel, New York, United States
     18:35-18:45 Introduction: Evolving approaches for managing progressive Crohn's Disease
    Jean-Frédéric Colombel, New York, United States
     18:45-19:00 Maximising outcomes with early effective pharmacologic treatment of Crohn's Disease
    Stefan Schreiber, Kiel, Germany
    19:00-19:15 Fistulising Crohn's Disease: Current treatment challenges
    Gert van Assche, Leuven, Blegium
    19:15-19:30 Transforming treatment of Fistulising Crohn's Disease: New data on stem-cell based approaches
    Damián García-Olmo, Madrid, Spain
    19:30-19:35 Panel discussion and audence Q&A
    All Faculty


    Satellite symposium 4c: Janssen
    Lehar 1-3, Congress Centre, Reed Messe Wien

    Janssen


    18:35-19:35 The road ahead: advancing treatment strategies for Crohn's Disease
    Séverine Vermeire, Leuven, Belgium
     18:35-18:40 Welcome & Introduction
    Séverine Vermeire, Leuven, Belgium
     18:40-18:50 Targeting IL-12/23 in Crohn's Disease: Update on evidence
    Iris Dotan, Tel Aviv, Israel
    18:50-19:30 Patient-case-based discussion: Making optimal choices to improve patient outcomes in Crohn's Disease
    Matthieu Allez, Paris, France
    Iris Dotan, Tel Aviv, Israel
    Séverine Vermeire, Leuven, Belgium
    19:30-19:35 Conclusions and close of meeting
    Séverine Vermeire, Leuven, Belgium

    Satellite symposium 4d: Ferring
    Strauss 1-2, Congress Centre, Reed Messe Wien

    Ferring

    18:35-19:35 Change management in IBD, are we mastering it?
    Subrata Ghosh, Birmingham, United Kingdom
     18:35-18:50 Keynote opening address
    Subrata Ghosh, Birmingham, United Kingdom
     18:50-19:10 Treat-to-target in Mild to Moderate IBD - what do we know from clinical studies
    Paolo Gionchetti, Bologna, Italy
    19:10-19:30 Real word data in IBD management - learnings from The Netherlands
    Bas Oldenburg, Utrecht, The Netherlands
    19:30-19:35 Discussions & Q&A

Leave a comment

You are commenting as guest.